Zhichun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhichun Liu has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Gang Wang
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China
41 shared publications Gang Wang
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China
24 shared publicationsNing Zhuo
Department of Nephrology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, 215002, China
13 shared publicationsLeixi Xue
Department of Rheumatology and Immunology, the Second Affiliated Hospital of Soochow University
7 shared publicationsDong Yan
Department of Rheumatology and Immunology Second Affiliated Hospital of Soochow University Suzhou China
6 shared publications- Leixi Xue
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
6 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1928854
Hypocomplementemia C3 and anti-SSB positivity: associated factors and a predictive model for hematological involvement in Sjögren’s disease
Objective: Hematological involvement occurs in over 20% of patients with Sjögren’s disease (SjD), yet its associated factors remain poorly characterized. This retrospective cross-sectional study aimed to evaluate clinical and immunological factors associated with concurrent hematological involvement in SjD using blood cell damage stratification. Methods: A total of 163 hospitalized SjD patients without recent high-dose glucocorticoids or potent immunosuppressants (2018–2024) were enrolled. Demographic data, clinical characteristics, laboratory parameters, and disease activity indices were collected. Patients were classified into two groups based on the presence or absence of baseline hematological involvement. Multivariable logistic regression identified factors independently associated with concurrent hematological involvement and constructed a cross-sectional classification model. The model’s discriminative performance was evaluated using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Results: Among 163 enrolled SjD patients, 70 (42.9%) had hematological involvement, while 93 (57.1%) did not. Compared with patients without hematological involvement, those with involvement had significantly higher levels of globulin (median 40 vs. 33 g/L), IgG (median 18.0 vs. 15.5 g/L), and modified ESSDAI scores (excluding the hematological domain, median 9.0 vs. 6.0), as well as lower C3 (median 0.74 vs. 0.86 g/L) and C4 levels (median 0.16 vs. 0.18 g/L) (all P < 0.05). Patients with multilineage cytopenia exhibited elevated IgG levels, increased disease activity, higher anti-SSB positivity rates, and reduced C3 levels. C3 hypocomplementemia (OR 0.21, 95% CI 0.02–2.67, P < 0.05) and anti-SSB positivity (OR 6.61, 95% CI 1.59–110, P < 0.05) were independently associated with concurrent hematological involvement. The combined model incorporating C3 and anti-SSB antibody yielded an AUC of 0.741 (95% CI: 0.642–0.841), outperforming either C3 (AUC = 0.633) or anti-SSB antibody (AUC = 0.656) when used alone. At the optimal cut-off value, the sensitivity and specificity were 76.7% and 68.4%, respectively. Conclusion: C3 hypocomplementemia and anti-SSB positivity are independently associated with hematological involvement in SjD, and their combination may serve as a preliminary cross-sectional tool for identifying such patients at initial evaluation, pending external validation. Routine C3 and anti-SSB measurement may be a useful, accessible marker for raising suspicion of cytopenia in clinical practice.
- 13 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1928854
Open AccessHypocomplementemia C3 and anti-SSB positivity: associated factors and a predictive model for hematological involvement in Sjögren’s disease
Objective: Hematological involvement occurs in over 20% of patients with Sjögren’s disease (SjD), yet its associated factors remain poorly characterized. This retrospective cross-sectional study aimed to evaluate clinical and immunological factors associated with concurrent hematological involvement in SjD using blood cell damage stratification. Methods: A total of 163 hospitalized SjD patients without recent high-dose glucocorticoids or potent immunosuppressants (2018–2024) were enrolled. Demographic data, clinical characteristics, laboratory parameters, and disease activity indices were collected. Patients were classified into two groups based on the presence or absence of baseline hematological involvement. Multivariable logistic regression identified factors independently associated with concurrent hematological involvement and constructed a cross-sectional classification model. The model’s discriminative performance was evaluated using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Results: Among 163 enrolled SjD patients, 70 (42.9%) had hematological involvement, while 93 (57.1%) did not. Compared with patients without hematological involvement, those with involvement had significantly higher levels of globulin (median 40 vs. 33 g/L), IgG (median 18.0 vs. 15.5 g/L), and modified ESSDAI scores (excluding the hematological domain, median 9.0 vs. 6.0), as well as lower C3 (median 0.74 vs. 0.86 g/L) and C4 levels (median 0.16 vs. 0.18 g/L) (all P < 0.05). Patients with multilineage cytopenia exhibited elevated IgG levels, increased disease activity, higher anti-SSB positivity rates, and reduced C3 levels. C3 hypocomplementemia (OR 0.21, 95% CI 0.02–2.67, P < 0.05) and anti-SSB positivity (OR 6.61, 95% CI 1.59–110, P < 0.05) were independently associated with concurrent hematological involvement. The combined model incorporating C3 and anti-SSB antibody yielded an AUC of 0.741 (95% CI: 0.642–0.841), outperforming either C3 (AUC = 0.633) or anti-SSB antibody (AUC = 0.656) when used alone. At the optimal cut-off value, the sensitivity and specificity were 76.7% and 68.4%, respectively. Conclusion: C3 hypocomplementemia and anti-SSB positivity are independently associated with hematological involvement in SjD, and their combination may serve as a preliminary cross-sectional tool for identifying such patients at initial evaluation, pending external validation. Routine C3 and anti-SSB measurement may be a useful, accessible marker for raising suspicion of cytopenia in clinical practice.
- 24 August 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (10) , 5963-5978
Mechanism-informed combination therapy and dynamic risk stratification in lupus nephritis: toward durable renal protection
- 24 August 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (10) , 5963-5978
Mechanism-informed combination therapy and dynamic risk stratification in lupus nephritis: toward durable renal protection
- Open Access
- 13 April 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (4) , e70436
Clinical Features and Associated Factors of Lupus Myocarditis: A Case‐Control Study
Objectives: This study aimed to explore the clinical characteristics of patients with lupus myocarditis (LM) and to evaluate the efficacy of rituximab (RTX) in LM treatment. Methods: The medical records of all patients with LM admitted to our hospital between January 2012 and March 2025 were retrospectively analyzed. Two control groups were established by randomly matching patients by sex and age at a 1:1 ratio: patients with systemic lupus erythematosus (SLE) without LM and patients with non‐SLE myocarditis. The SLE disease activity index 2 K (SLEDAI 2 K) score and Systemic Lupus Erythematosus Disease Activity Score (SLE‐DAS) were calculated to evaluate SLE disease activity. Results: A total of 22 patients with LM were enrolled. Patients with LM had a higher incidence of lupus nephritis and a higher positivity rate for anti‐SSB antibodies than those with SLE without LM. Furthermore, patients with SLE with LM had significantly higher SLE‐DAS than those without LM, although no statistical difference in SLEDAI 2 K score was observed between the groups. Wall motion abnormalities, valvular regurgitation, and decreased left ventricular ejection fraction (LVEF) were more frequent in patients with LM than in those with non‐SLE myocarditis. All patients with LM received corticosteroid treatment, with three of them receiving RTX in addition to standard therapy. With a median follow‐up of 4 (range, 1–24) months, 2 patients (9.1%) died due to heart failure, and the remaining 20 achieved symptom remission. Moreover, 13 patients underwent follow‐up echocardiography, which showed a significant improvement in LVEF. The three patients treated with RTX achieved clinical improvement within a mean of 2 weeks, enabling rapid glucocorticoid tapering. Conclusions: Patients with LM more frequently present with lupus nephritis and positive anti‐SSB antibodies, are more likely to have echocardiographic abnormalities, and exhibit a higher mortality rate. In addition, RTX is a promising drug for LM treatment.
- 13 April 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (4) , e70436
Open AccessClinical Features and Associated Factors of Lupus Myocarditis: A Case‐Control Study
Objectives: This study aimed to explore the clinical characteristics of patients with lupus myocarditis (LM) and to evaluate the efficacy of rituximab (RTX) in LM treatment. Methods: The medical records of all patients with LM admitted to our hospital between January 2012 and March 2025 were retrospectively analyzed. Two control groups were established by randomly matching patients by sex and age at a 1:1 ratio: patients with systemic lupus erythematosus (SLE) without LM and patients with non‐SLE myocarditis. The SLE disease activity index 2 K (SLEDAI 2 K) score and Systemic Lupus Erythematosus Disease Activity Score (SLE‐DAS) were calculated to evaluate SLE disease activity. Results: A total of 22 patients with LM were enrolled. Patients with LM had a higher incidence of lupus nephritis and a higher positivity rate for anti‐SSB antibodies than those with SLE without LM. Furthermore, patients with SLE with LM had significantly higher SLE‐DAS than those without LM, although no statistical difference in SLEDAI 2 K score was observed between the groups. Wall motion abnormalities, valvular regurgitation, and decreased left ventricular ejection fraction (LVEF) were more frequent in patients with LM than in those with non‐SLE myocarditis. All patients with LM received corticosteroid treatment, with three of them receiving RTX in addition to standard therapy. With a median follow‐up of 4 (range, 1–24) months, 2 patients (9.1%) died due to heart failure, and the remaining 20 achieved symptom remission. Moreover, 13 patients underwent follow‐up echocardiography, which showed a significant improvement in LVEF. The three patients treated with RTX achieved clinical improvement within a mean of 2 weeks, enabling rapid glucocorticoid tapering. Conclusions: Patients with LM more frequently present with lupus nephritis and positive anti‐SSB antibodies, are more likely to have echocardiographic abnormalities, and exhibit a higher mortality rate. In addition, RTX is a promising drug for LM treatment.
- Retraction
- 12 March 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (8) , 3355
Retraction Note: Anxiety and depression among patients with end-stage renal disease undergoing hemodialysis
- 12 March 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (8) , 3355
RetractionRetraction Note: Anxiety and depression among patients with end-stage renal disease undergoing hemodialysis
- RetractionOpen Access
- 11 March 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (8) , 1
Retraction Note: Depression is a mediating variable between sleep disorders and frailty
- 11 March 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (8) , 1
RetractionOpen AccessRetraction Note: Depression is a mediating variable between sleep disorders and frailty
- RetractionOpen Access
- 11 March 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (8) , 1
Retraction Note: Short or long sleep duration was associated with chronic kidney disease in the general population
- 11 March 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (8) , 1
RetractionOpen AccessRetraction Note: Short or long sleep duration was associated with chronic kidney disease in the general population
- RetractionOpen Access
- 11 March 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (5) , 1893
Retraction Note: Higher cardiometabolic index was independently associated with higher chronic kidney disease risk in the general population
- 11 March 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (5) , 1893
RetractionOpen AccessRetraction Note: Higher cardiometabolic index was independently associated with higher chronic kidney disease risk in the general population
- Open Access
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1)
The TWEAK–HOIP–HuR Axis: A Novel Mechanism of AMPK Inactivation and Metabolic Reprogramming in Lupus Nephritis Mesangial Cells Hyperproliferation
Cellular proliferation is intrinsically coupled to metabolic reprogramming, a conserved biological association that modulates the progression of diverse proliferative pathologies. In the present study, we unveil a novel mechanistic link between tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) signaling and Human antigen R (HuR)‐driven metabolic alterations in lupus nephritis (LN), a progressive renal disorder characterized by mesangial cells (MCs) hyperproliferation and glomerular dysfunction. We demonstrate that TWEAK stimulation elicits linear ubiquitination of AMP‐activated protein kinase (AMPK)—a master regulator of cellular energy metabolism—mediated by the E3 ubiquitin ligase HOIL‐1‐interacting protein (HOIP). This posttranslational modification directly results in the functional inactivation of AMPK. Notably, suppressed AMPK activity drives the nuclear export of HuR, a ubiquitously expressed RNA‐binding protein, leading to its subsequent accumulation in the cytoplasmic compartment. In the cytosol, HuR selectively binds to and stabilizes the mRNAs of key cell cycle regulators, with Cyclin D1 being a primary target. This stabilization of Cyclin D1 mRNA ultimately promotes aberrant MCs proliferation, a pathological hallmark of LN. To validate the functional relevance of the pathogenesis, we performed HOIP knockdown experiments in MCs. Consistent with our mechanistic model, HOIP depletion significantly restored AMPK phosphorylation (a well‐established surrogate marker of AMPK activation), suppressed HuR cytoplasmic shuttling, reduced Cyclin D1 expression at both the transcriptional and translational levels, and ultimately inhibited aberrant MCs proliferation in vitro. Collectively, our results establish the TWEAK–HOIP–AMPK–HuR axis as a critical signaling axis that couples metabolic dysfunction to dysregulated cell cycle progression in LN. This work not only provides critical new mechanistic insights into the pathogenesis of mesangial hyperproliferation in LN but also highlights potential therapeutic targets, including HOIP and cytoplasmic HuR, for the development of targeted treatments for LN and other renal diseases characterized by abnormal MCs proliferation.
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1)
Open AccessThe TWEAK–HOIP–HuR Axis: A Novel Mechanism of AMPK Inactivation and Metabolic Reprogramming in Lupus Nephritis Mesangial Cells Hyperproliferation
Cellular proliferation is intrinsically coupled to metabolic reprogramming, a conserved biological association that modulates the progression of diverse proliferative pathologies. In the present study, we unveil a novel mechanistic link between tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) signaling and Human antigen R (HuR)‐driven metabolic alterations in lupus nephritis (LN), a progressive renal disorder characterized by mesangial cells (MCs) hyperproliferation and glomerular dysfunction. We demonstrate that TWEAK stimulation elicits linear ubiquitination of AMP‐activated protein kinase (AMPK)—a master regulator of cellular energy metabolism—mediated by the E3 ubiquitin ligase HOIL‐1‐interacting protein (HOIP). This posttranslational modification directly results in the functional inactivation of AMPK. Notably, suppressed AMPK activity drives the nuclear export of HuR, a ubiquitously expressed RNA‐binding protein, leading to its subsequent accumulation in the cytoplasmic compartment. In the cytosol, HuR selectively binds to and stabilizes the mRNAs of key cell cycle regulators, with Cyclin D1 being a primary target. This stabilization of Cyclin D1 mRNA ultimately promotes aberrant MCs proliferation, a pathological hallmark of LN. To validate the functional relevance of the pathogenesis, we performed HOIP knockdown experiments in MCs. Consistent with our mechanistic model, HOIP depletion significantly restored AMPK phosphorylation (a well‐established surrogate marker of AMPK activation), suppressed HuR cytoplasmic shuttling, reduced Cyclin D1 expression at both the transcriptional and translational levels, and ultimately inhibited aberrant MCs proliferation in vitro. Collectively, our results establish the TWEAK–HOIP–AMPK–HuR axis as a critical signaling axis that couples metabolic dysfunction to dysregulated cell cycle progression in LN. This work not only provides critical new mechanistic insights into the pathogenesis of mesangial hyperproliferation in LN but also highlights potential therapeutic targets, including HOIP and cytoplasmic HuR, for the development of targeted treatments for LN and other renal diseases characterized by abnormal MCs proliferation.
- Open Access
- 10 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1642682
Serum lactate dehydrogenase and rapidly progressive interstitial lung disease are associated with increased mortality in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis
Objective: This study aims to evaluate the clinical characteristics and prognostic significance of serum lactate dehydrogenase (LDH) in patients with anti-MDA5+ dermatomyositis (anti-MDA5+ DM). Methods: We assessed 246 consecutive patients with anti-MDA5+ DM. The patients were divided into two groups based on LDH levels: the LDH ≤ 338 U/L group and the LDH > 338 U/L group. We compared the clinical characteristics, laboratory findings, and long-term prognosis between the two groups. Results: Overall, the one-year mortality rate in patients with anti-MDA5+ DM was high, at 24.39% (60/246). LDH levels exhibited a nonlinear, inverted S-shaped relationship with the overall mortality risk in anti-MDA5+ DM patients (nonlinear P = 0.001). Patients in the LDH > 338 U/L group had significantly higher levels of ALT [64.0 (32.0, 121.0) vs 40.0 (23.0, 66.5), P 338 U/L and the presence of RPILD were associated with poor prognosis [hazard ratios of 2.253 (95% CI 1.258, 4.035, P = 0.006) and 10.293 (95% CI 4.683, 22.623, P < 0.001), respectively]. Conclusion: Patients with different LDH levels exhibit distinct clinical characteristics, laboratory findings, and long-term prognosis. Elevated LDH levels (> 338 U/L) and the presence of RPILD are associated with poor prognosis.
- 10 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1642682
Open AccessSerum lactate dehydrogenase and rapidly progressive interstitial lung disease are associated with increased mortality in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis
Objective: This study aims to evaluate the clinical characteristics and prognostic significance of serum lactate dehydrogenase (LDH) in patients with anti-MDA5+ dermatomyositis (anti-MDA5+ DM). Methods: We assessed 246 consecutive patients with anti-MDA5+ DM. The patients were divided into two groups based on LDH levels: the LDH ≤ 338 U/L group and the LDH > 338 U/L group. We compared the clinical characteristics, laboratory findings, and long-term prognosis between the two groups. Results: Overall, the one-year mortality rate in patients with anti-MDA5+ DM was high, at 24.39% (60/246). LDH levels exhibited a nonlinear, inverted S-shaped relationship with the overall mortality risk in anti-MDA5+ DM patients (nonlinear P = 0.001). Patients in the LDH > 338 U/L group had significantly higher levels of ALT [64.0 (32.0, 121.0) vs 40.0 (23.0, 66.5), P 338 U/L and the presence of RPILD were associated with poor prognosis [hazard ratios of 2.253 (95% CI 1.258, 4.035, P = 0.006) and 10.293 (95% CI 4.683, 22.623, P < 0.001), respectively]. Conclusion: Patients with different LDH levels exhibit distinct clinical characteristics, laboratory findings, and long-term prognosis. Elevated LDH levels (> 338 U/L) and the presence of RPILD are associated with poor prognosis.